64 related articles for article (PubMed ID: 18467270)
1. Breast cancer expression of E-cadherin does not differ between patients with positive and negative oncological history.
Bruzewicz S; Matkowski R; Swiatoniowski G; Suder E; Setta M; Połozowski A; Zychowicz K; Szynglarewicz B; Kornafel J
Adv Med Sci; 2008; 53(2):251-5. PubMed ID: 18467270
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin expression in invasive breast cancer.
Suciu C; Cîmpean AM; Mureşan AM; Izvernariu D; Raica M
Rom J Morphol Embryol; 2008; 49(4):517-23. PubMed ID: 19050801
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters.
Qureshi HS; Linden MD; Divine G; Raju UB
Am J Clin Pathol; 2006 Mar; 125(3):377-85. PubMed ID: 16613340
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin and fibronectin expressions have no prognostic role in stage II ductal breast cancer.
Swiatoniowski G; Matkowski R; Suder E; Bruzewicz S; Setta M; Kornafel J; Polozowski A; Surowiak P
Anticancer Res; 2005; 25(4):2879-83. PubMed ID: 16080541
[TBL] [Abstract][Full Text] [Related]
5. [Importance of E-cadherin; expression in the inmunohistochemical diagnosis of breast cancer].
García Tamayo J; Blasco Olaetxea E; Morales A; Molina J; Guzmán Bistoni C; Méndez V
Invest Clin; 2006 Dec; 47(4):371-83. PubMed ID: 17176905
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
[TBL] [Abstract][Full Text] [Related]
7. [Expression of E-cadherine as a differential diagnostic fest for lobular infiltrative breast cancers].
Chipysheva TA; Ermilova VD; Vishnevskaia IaV; Vasil'ev IuM
Arkh Patol; 2005; 67(6):24-7. PubMed ID: 16405017
[TBL] [Abstract][Full Text] [Related]
8. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
9. Hereditary breast cancer in Finnish women.
Doepel M; Kellokumpu IH; v Smitten KA
Eur J Surg; 1995 Nov; 161(11):805-9. PubMed ID: 8749212
[TBL] [Abstract][Full Text] [Related]
10. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
[TBL] [Abstract][Full Text] [Related]
11. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
12. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.
Koo JS; Jung W; Jeong J
Jpn J Clin Oncol; 2009 Sep; 39(9):560-8. PubMed ID: 19531543
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor A (VEGF A) as individual prognostic factor in invasive breast carcinoma.
Cîmpean AM; Raica M; Suciu C; Tătucu D; Sârb S; Mureşan AM
Rom J Morphol Embryol; 2008; 49(3):303-8. PubMed ID: 18758633
[TBL] [Abstract][Full Text] [Related]
14. Atypia and Ki-67 expression from ductal lavage in women at different risk for breast cancer.
Cazzaniga M; Severi G; Casadio C; Chiapparini L; Veronesi U; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1311-5. PubMed ID: 16835329
[TBL] [Abstract][Full Text] [Related]
15. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of TopBP1 in breast cancer.
Going JJ; Nixon C; Dornan ES; Boner W; Donaldson MM; Morgan IM
Histopathology; 2007 Mar; 50(4):418-24. PubMed ID: 17448016
[TBL] [Abstract][Full Text] [Related]
17. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
18. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of cyclin E in low-risk node negative breast cancer.
Ahlin C; Gruhne B; Holmqvist M; Zetterberg A; Fjällskog ML
Acta Oncol; 2008; 47(8):1539-45. PubMed ID: 18607847
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine carcinomas of the breast.
Rovera F; Masciocchi P; Coglitore A; La Rosa S; Dionigi G; Marelli M; Boni L; Dionigi R
Int J Surg; 2008; 6 Suppl 1():S113-5. PubMed ID: 19167937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
